author-photo

Axel Hinke

Ruhr University Bochum

194

Papers

6838

Citations

Citation Trend

Filter By

Papers (132) Sort By

Journal Conference Others

Treatment breaks in first line treatment of advanced colorectal cancer: an individual patient data meta-analysis

2021 Cancer Treatment Reviews
Show All
- Source
- Cite
- Save
Citations (2)
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.

2021 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.

2021 Cancer Treatment Reviews
Show All
- Source
- Cite
- Save
Citations (0)
RAMIRIS: Wirksamkeit von Ramucirumab plus FOLFIRI vs. Ramucirumab plus Paclitaxel bei Patienten mit fortgeschrittenem oder metastasiertem Adenokarzinom des Magens oder des gastroösophagealen Übergangs, die auf eine Erstlinientherapie progredient sind – eine randomisierte Phase-II/III-Studie der AIO

2020 The Forum
Show All
- Source
- Cite
- Save
Citations (0)
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results

2020 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (6)
1495P FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Final results from the phase II RAMIRIS Study of the AIO

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)